Search Results - "Yetzer, Ellen S"

Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a–Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders by GANE, Edward J, ROUZIER, Régine, KULKARNI, Rohit, YING ZHANG, SMITH, Patrick, YETZER, Ellen S, SHULMAN, Nancy S, WIERCINSKA-DRAPALO, Alicja, LARREY, Dominique G, MORCOS, Peter N, BRENNAN, Barbara J, LE POGAM, Sophie, NAJERA, Isabel, PETRIC, Rosemary, TRAN, Jonathan Q

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study by Gane, Edward J., Pockros, Paul J., Zeuzem, Stefan, Marcellin, Patrick, Shikhman, Anna, Bernaards, Coen, Zhou, Julian, Yetzer, Ellen S., Ballester, Rosa, Dwyer, Cindy, Tong, Xiao, Nájera, Isabel, Bertasso, Anne, Hammond, Janet, Kindrick, Amy, Morcos, Peter N., Smith, Patrick, Stancic, Saray, Shulman, Nancy S.

“…Background & Aims Safety and tolerability of peginterferon‐based hepatitis C virus (HCV) infection therapy remains suboptimal, even when direct‐acting…”
Get full text

Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection by Marcellin, Patrick, Cooper, Curtis, Balart, Luis, Larrey, Dominique, Box, Terry, Yoshida, Eric, Lawitz, Eric, Buggisch, Peter, Ferenci, Peter, Weltman, Martin, Labriola–Tompkins, Emily, Le Pogam, Sophie, Nájera, Isabel, Thomas, Denise, Hooper, Gregory, Shulman, Nancy S, Zhang, Ying, Navarro, Mercidita T, Lim, Chin Yin, Brunda, Michael, Terrault, Norah A, Yetzer, Ellen S

“…Background & Aims The combination of a hepatitis C virus (HCV) protease inhibitor, peginterferon, and ribavirin is the standard of care for patients with HCV…”
Get full text

DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4 by Everson, Gregory, Cooper, Curtis, Hézode, Christophe, Shiffman, Mitchell L., Yoshida, Eric, Beltran-Jaramillo, Teresita, Andreone, Pietro, Bruno, Savino, Ferenci, Peter, Zeuzem, Stefan, Brunda, Michael, Le Pogam, Sophie, Nájera, Isabel, Zhou, Julian, Navarro, Mercidita T., Voulgari, Athina, Shulman, Nancy S., Yetzer, Ellen S.

“…Background & Aims Danoprevir is a hepatitis C virus (HCV) protease inhibitor with activity against genotypes (G)1/G4, which is maintained at lower doses by…”
Get full text

Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin by Feld, Jordan J, Jacobson, Ira M, Jensen, Donald M, Foster, Graham R, Pol, Stanislas, Tam, Edward, Jablkowski, Maciej, Berak, Hanna, Vierling, John M, Yoshida, Eric M, Perez-Gomez, Héctor R, Scalori, Astrid, Hooper, Gregory J, Tavel, Jorge A, Navarro, Mercidita T, Shahdad, Saba, Kulkarni, Rohit, Pogam, Sophie Le, Nájera, Isabel, Eng, Simon, Lim, Chin Yin, Shulman, Nancy S, Yetzer, Ellen S

“…Graphical abstract…”
Get full text

Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection by Eron, J J, Yetzer, E S, Ruane, P J, Becker, S, Sawyer, G A, Fisher, R L, Tolson, J M, Shaefer, M S

“…A randomized, open-label, multicenter study to establish clinical equivalence (non-inferiority) of a regimen employing a lamivudine 150 mg/zidovudine 300 mg…”
Get full text